Long-term outcome of patients who receive ketamine during research

Biological Psychiatry

Volumn 49, Issue 10, 2001, Pages 869-875

  Lahti, Adrienne C ^a,b   Warfel, Dale ^a   Michaelidis, Tamara ^a   Weiler, Martin A ^a   Frey, Kristin ^a   Tamminga, Carol A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Spring Grove Hospital Center   (United States)

Author keywords

Challenge; Ketamine; Outcome; Research ethics; Schizophrenia; Symptom provocation

Indexed keywords

KETAMINE; NEUROLEPTIC AGENT;

ADULT; ANIMAL MODEL; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; MEDICAL RESEARCH; MENTAL DISEASE; MENTAL HEALTH CARE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SCHOOL CHILD; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KETAMINE; MALE; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0035873010     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01037-4     Document Type: Article

References (36)

1. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al (2000): Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatry 57:270-276.
2. Andreasen NC (1984): The Scale for the Assessment of Negative Symptoms. Iowa City: University of Iowa.
3. Anis NA, Berry SC, Burton NR, Lodge D (1983): The dissociative anesthetics ketamine and phencyclidine selectively reduce excitation of central mammalian neurons by N-methyl-D-aspartate. Br J Pharmacol 79:5654-5675.
4. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, et al (1998): Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach. Synapse 29:142-147.
5. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997): Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154:805-811.
6. Carpenter WT (1997): The risk of medication-free research. Schizophr Bull 23:11-18.
7. Carpenter WT (1999): The schizophrenia ketamine challenge study debate. Biol Psychiatry 46:1081-1091.
8. Corrsen G, Reves JG, Stanley TH (1988): Dissociative anesthesia: In: Corrsen G, Reves JG, Stanley TH, editors. Intravenous Anesthesia and Analgesia. Philadelphia: Lea and Febiger, 99-173.
9. Craig TJ, Bromet EJ, Fennig S, ManenbergKarant M, Lavelle J, Galambos N (2000): Is there an association between duration of un-treated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry 157:60-66.
10. Harborne GC, Watson FL, Healy DT, Groves E (1996): The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. J Psychopharmacol 10:134-140.
11. Hersack RA (1994): Ketamine's psychological effects do not contraindicate its use based on a patient's occupation. Aviat Space Environ Med 65:1041-1046.
12. Ishihara H, Kudo H, Murakawa T, Kudo A, Takahashi S, Matsuki A (1997): Uneventful total intravenous anaesthesia with ketamine for schizophrenic surgical patients. Eur J Anaesthesiol 14:47-51.
13. Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
14. Johnstone EC, Owens DGC, Crow TJ, Davis JM (1999): Does a four-week delay in the introduction of medication alter the course of functional psychosis? J Psychopharmacol 13:238-244.
15. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, et al (1998): Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 135:213-229.
16. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremmer JD, et al (1994): Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 51:199-214.
17. Lahti AC, Holcomb HH, Gao XM, Tamminga CA (1999): NMDA-sensitive glutamate antagonism: A human model for psychosis. Neuropsychopharmacology 21:8158-8169.
18. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995a): Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6:869-872.
19. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995b): Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19.
20. LaPorte DJ, Lahti AC, Koffel B, Tamminga CA (1996): Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients. J Psychiatr Res 30:321-330.
21. Luby LD, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959): Study of a new schizophrenomimetic drug - sernyl. Arch Gen Psychiatry 81:363-369.
22. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A (1997): Clozapine blunts N-methyl-D-Aspartate antagonist-induced psychosis: A study with ketamine. Biol Psychiatry 42:664-668.
23. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al (1996): NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307.
24. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, et al (1999a): Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106-118.
25. Newcomer JW, Farber NB, Selke G, Melson AK, Jevtovic-Todorovic V, Olney JW (1999b): Guanabenz prevention of NMDA antagonist-induced mental symptoms in healthy humans. Schizophr Res 36:311.
26. Oranje B, vanBerckel BN, Kemner C, vanRee JM, Kahn RS, Verbaten MN (2000): The effects of a sub-anaesthetic dose of ketmaine on human selective attention. Neuropsychopharmacology 22:293-302.
27. Overall JF, Gorham DR (1962): The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
28. Pearlson GD (1981): Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Med J 148:25-33.
29. Radant AD, Bowdle TA, Cowley DS, Kharasch ED, Roy-Byrne PP (1998): Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 19:434-444.
30. Reich DL, Silvay G (1989): Ketamine: An update on the first twenty-five years of clinical experience. Can J Anaesth 36:186-197.
31. Schorn TOF, Whitman JG (1980): Are there long-term effects of ketamine on the central nervous system? Br J Anaesth 52:967-968.
32. van Berckel BN, Oranje B, van Ree JM, Verbaten MN, Kahn RS (1998): The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology 137:271-281.
33. Vollenweider EX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, et al (1997): Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [′∼F∼fluorodeoxyglucose] (FDG). Eur Neuropsychopharmacol 7:9-24.
34. Weiler MA, Thaker GK, Lahti AC, Tamminga CA (2000): Effects of ketamine on eye movements. Neuropsychopharmacology 23:645-653.
35. White PF, Way WL, Trevor AJ (1982): Ketamine-its pharmacology and therapeutic uses. Anesthesiology 56:119-136.
36. Wyatt JR (1997): Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull 23:3-9.